Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 91 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Donepezil placebo Clear all
Completed Phase 1 Interventional Results available

Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)

NCT06285240
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
MK-1167, Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
3
States / cities
Hallandale, Florida • Decatur, Georgia • Savannah, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

Donepezil and Vitamin E to Prevent Side Effects Caused By Radiation Therapy to the Head in Patients Receiving Treatment for Small Cell Lung Cancer

NCT00006349
View directory record Official record
Conditions
Cognitive/Functional Effects, Delirium, Depression, Lung Cancer, Radiation Toxicity
Interventions
vitamin E, donepezil hydrochloride, placebo
Dietary Supplement · Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
15
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2016 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 3 Interventional Results available

Evaluating The Efficacy And Safety Of Donepezil Hydrochloride (Aricept) In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome, Aged 6 To 10

NCT00754013
View directory record Official record
Conditions
Down Syndrome, Cognitive Dysfunction
Interventions
Aricept (Donepezil hydrochloride), Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
6 Years to 10 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
San Antonio, Texas • Herndon, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease

NCT00428090
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Rosiglitazone
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 90 Years
Enrollment
862 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
41
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 34 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Intepirdine (RVT-101) in Subjects With Mild to Moderate Alzheimer's Disease on Donepezil: MINDSET Study

NCT02585934
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RVT-101, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years to 85 Years
Enrollment
1,315 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
61
States / cities
Phoenix, Arizona • Tucson, Arizona • Encino, California + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2018 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease

NCT02087865
View directory record Official record
Conditions
Genetic Risk for Alzheimer's Disease
Interventions
donepezil HCL, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
60 Years to 75 Years
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of TAK-071 in Healthy Participants and Participants With Mild Cognitive Impairment/Mild Alzheimer Disease and Relative Bioavailability (BA) and Food Effect of TAK-071 in Healthy Participants

NCT02769065
View directory record Official record
Conditions
Alzheimer Disease, Healthy Volunteers
Interventions
TAK-071, Donepezil, TAK-071 Placebo, Donepezil Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 90 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2019 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Early Phase 1 Interventional

Improving Walking Automaticity in Parkinson's Disease: Levodopa or Donepezil

NCT03599726
View directory record Official record
Conditions
Parkinson Disease
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 10, 2020 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

A Trial of the Drug Donepezil for Sleep Enhancement and Behavioral Change in Children With Autism

NCT01887132
View directory record Official record
Conditions
Autism Spectrum Disorders
Interventions
Donepezil, Placebo
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
24 Months to 50 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 24, 2017 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 1 Interventional Results available

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT04730635
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
55 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Long Beach, California • Hallandale, Florida • Lady Lake, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study for Subjects With Mild-to-Moderate Alzheimer's Disease

NCT00948909
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, ABT-126, donepezil
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
55 Years to 90 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
3
States / cities
Fresno, California • West Palm Beach, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Effect of Different Doses of SAR110894 on Cognition in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT01266525
View directory record Official record
Conditions
Dementia Alzheimer's Type
Interventions
SAR110894, placebo (for SAR110894), Donepezil
Drug
Lead sponsor
Sanofi
Industry
Eligibility
55 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
27
States / cities
Gilbert, Arizona • Phoenix, Arizona • Costa Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2016 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Evaluating The Safety Of Donepezil Hydrochloride (Aricept) For Up To 1 Year In The Treatment Of The Cognitive Dysfunction Exhibited By Children With Down Syndrome - Follow-Up To A 10-Week, Double-Blind, Placebo-Controlled Trial

NCT00675025
View directory record Official record
Conditions
Down Syndrome
Interventions
Donepezil hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
10 Years to 17 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
31
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2021 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 2 Interventional Results available

Donepezil HCl & Cognitive Deficits in Autism

NCT00047697
View directory record Official record
Conditions
Autistic Disorder
Interventions
Donepezil HCl, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
8 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Sep 11, 2026, 6:17 AM EDT
Withdrawn Phase 1 Interventional

A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease

NCT03316898
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AGN-242071, Placebo, Donepezil, Memantine
Drug
Lead sponsor
Allergan
Industry
Eligibility
55 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
6
States / cities
Costa Mesa, California • Irvine, California • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2018 · Synced Sep 11, 2026, 6:17 AM EDT
Withdrawn Phase 4 Interventional

Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease

NCT00711204
View directory record Official record
Conditions
Severe Alzheimer's Disease
Interventions
Donepezil Hydrochloride (Aricept)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2012 · Synced Sep 11, 2026, 6:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Evaluation of Three Potential Central Nervous System (CNS) Pretreatments for Soman Exposure on Human Performance

NCT01194336
View directory record Official record
Conditions
Biomarkers, Pharmacological
Interventions
Huperzine A, Donepezil, Galantamine, Placebo
Drug · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 39 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 4 Interventional Results available

The Impact of Arousal Threshold in Obstructive Sleep Apnea

NCT02264353
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Donepezil, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 70 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 7, 2019 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease

NCT00096473
View directory record Official record
Conditions
Alzheimer's Disease, Dementia
Interventions
Donepezil hydrochloride
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
50 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
28
States / cities
Northport, Alabama • Phoenix, Arizona • Sun City, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2011 · Synced Sep 11, 2026, 6:17 AM EDT
Active, not recruiting Early Phase 1 Interventional

Effect of Donepezil on Speech Recognition in Cochlear Implant Users

NCT05438264
View directory record Official record
Conditions
Bilateral Sensorineural Hearing Loss
Interventions
Donepezil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional

The Effect of Donepezil on Glycemic Control in Type II Diabetics

NCT04507438
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Donepezil 5-10 Mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
51 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Easton, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Efficacy, Safety, & Tolerability of AZD3480 Patients With Mild to Moderate Dementia of the Alzheimer's Type (AD)

NCT01466088
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Donepezil, AZD3480
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
3
States / cities
Phoenix, Arizona • Brooksville, Florida • Hallandale, Florida
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 11, 2026, 6:17 AM EDT
Terminated Phase 2 Interventional Results available

Study Comparing 3 Dosage Levels Of SAM-531 In Outpatients With Mild To Moderate Alzheimer Disease

NCT00895895
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Placebo, SAM-531 1.5 mg, SAM-531 3.0 mg, SAM-531 5.0 mg, Donepezil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
37
States / cities
Phoenix, Arizona • Costa Mesa, California • Fresno, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 11, 2026, 6:17 AM EDT
Completed Phase 2 Interventional

Preliminary Efficacy and Safety Study of ST101 Plus Aricept in Alzheimer's Disease

NCT00842816
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ST101, Placebo
Drug
Lead sponsor
Sonexa Therapeutics, Inc.
Industry
Eligibility
50 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
27
States / cities
Tucson, Arizona • Costa Mesa, California • Redlands, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Sep 11, 2026, 6:17 AM EDT